Lucrezia Laterza

Dr. Lucrezia Laterza

Digestive Disease Center, CEMAD, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
FSFRANCO SCALDAFERRI
FRANCO SCALDAFERRI
VGViviana Gerardi
Viviana Gerardi
LLLoris Lopetuso
Loris Lopetuso
FZFabio Del Zompo
Fabio Del Zompo
FMFrancesca Mangiola
Francesca Mangiola
AGAntonio Gasbarrini
Antonio Gasbarrini
Inflammatory bowel diseases are chronic diseases affecting the gastrointestinal tract, whose major forms are represented by Crohn’s disease (CD) and ulcerative colitis (UC). Their etiology is still unclear, although several factors have been identified as major determinants for induction or relapses. Among these, the role of the “forgotten organ”, gut microbiota, has become more appreciated in recent years. The delicate symbiotic relationship between the gut microbiota and the host appears to be lost in IBD. In this perspective, several studies have been conducted to assess the role of prebiotics and probiotics in gut microbiota modulation. This is a minireview aimed to address in an easy format (simple questions-simple answers) some common issues about the theme. An update on the role of selected constituents of gut microbiota in the pathogenesis of IBD is presented together with the analysis of the efficacy of gut microbiota modulation by prebiotics and probiotics administration in the management of IBD.

1 May 2016 in Mediterranean Journal of Hematology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
Lucrezia LaterzaLucrezia Laterza
Lucrezia Laterza
GRGianenrico Rizzatti
Gianenrico Rizzatti
Eleonora GaetaniEleonora Gaetani
Eleonora Gaetani
PCPatrizia Chiusolo
Patrizia Chiusolo
AGAntonio Gasbarrini
Antonio Gasbarrini
Gutmicrobiotahas gainedincreasinginterestin the pathogenesisofimmune-related diseases. We reviewedtherole ofgutmicrobiotain the normaldevelopmentof immune systemand its involvementin graft-versus-hostdisease, focusingon dataavailableon humans.Gutmicrobiotahas gainedincreasinginterestin the pathogenesisofimmune-related diseases. We reviewedtherole ofgutmicrobiotain the normaldevelopmentof immune systemand its involvementin graft-versus-hostdisease, focusingon dataavailableon humans.

20 March 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
Giuseppe MaranoGiuseppe Marano
Giuseppe Marano
Marianna MazzaMarianna Mazza
Marianna Mazza
FLFrancesco Maria Lisci
Francesco Maria Lisci
MCMichele Ciliberto
Michele Ciliberto
GTGianandrea Traversi
Gianandrea Traversi
Eleonora GaetaniEleonora Gaetani
Eleonora Gaetani
There is growing interest in the role that the intestinal microbiota and the related autoimmune processes may have in the genesis and presentation of some psychiatric diseases. An alteration in the communication of the microbiota–gut–brain axis, which constitutes a communicative model between the central nervous system (CNS) and the gastro-enteric tract, has been identified as one of the possible causes of some psychiatric diseases. The purpose of this narrative review is to describe evidence supporting a role of the gut microbiota in psychiatric diseases and the impact of diet on microbiota and mental health. Change in the composition of the gut microbiota could determine an increase in the permeability of the intestinal barrier, leading to a cytokine storm. This could trigger a systemic inflammatory activation and immune response: this series of events could have repercussions on the release of some neurotransmitters, altering the activity of the hypothalamic–pituitary–adrenal axis, and reducing the presence of trophic brain factors. Although gut microbiota and psychiatric disorders seem to be connected, more effort is needed to understand the potential causative mechanisms underlying the interactions between these systems.

4 February 2013 in Rheumatology
Verified
Journal Article
Open access
PDF file
ESEdoardo Vincenzo Savarino
Edoardo Vincenzo Savarino
FMFederico Mei
Federico Mei
APAndrea Parodi
Andrea Parodi
MGMassimo Ghio
Massimo Ghio
MFManuele Furnari
Manuele Furnari
AGAntonio Gasbarrini
Antonio Gasbarrini
Objectives. SSc is a clinically heterogeneous and generalized disease, characterized by thickness of the connective tissue of the skin and internal organs, such as the digestive tract, impairing gastrointestinal (GI) motility. Our aim is to evaluate retrospectively abnormalities of oesophageal motility, gastric emptying, oro-cecal transit time (OCTT) and small intestine bacterial overgrowth (SIBO) in a large cohort of SSc patients. Methods. Ninety-nine SSc patients were included in the study. Forty-two patients underwent oesophageal conventional manometry, 45 performed a [13C]octanoic acid breath test to measure gastric emptying time and all 99 patients performed a lactulose breath test in order to evaluate OCTT and SIBO. Data were compared with healthy controls. Results. In SSc patients, median lower oesophageal sphincter (LOS) pressure [14 mmHg (25th–75th; 8–19) vs 24 mmHg (19–28); P < 0.01] and median wave amplitude [30 mmHg (16–70) vs 72 mmHg (48–96); P < 0.01] were lower than in controls. Oesophageal involvement, defined as reduced LOS pressure and ineffective oesophageal motility pattern, was encountered in 70% of SSc patients. A delayed gastric emptying time was present in 38% of SSc patients: mean t½ was 141 ± 79 min vs 90 ± 40 min of controls (P < 0.01). Also, OCTT was significantly delayed in SSc: median OCTT was 160 min (25th–75th; 135–180) vs 105 min (25th–75th; 90–135) of controls (P < 0.01). SIBO was observed in 46% of SSc compared with 5% of controls (P < 0.01). Conclusion. GI involvement is very frequent in SSc patients. Oesophagus and small bowel are more frequently impaired, whereas delayed gastric emptying is less common.

24 July 2014 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
Gianluca IaniroGianluca Ianiro
Gianluca Ianiro
GBGiovanni Bruno
Giovanni Bruno
LLLoris Lopetuso
Loris Lopetuso
FBFrancesca Bartoli Beghella
Francesca Bartoli Beghella
Lucrezia LaterzaLucrezia Laterza
Lucrezia Laterza
AGAntonio Gasbarrini
Antonio Gasbarrini
Although several studies have been published on the gut microbiota composition, they are mainly focused on bacteria. Therefore, the world of gut yeasts, the “gut mycome”, is still unclear. Over the last years, brand new gut microbiota analysis techniques have been applied to the study of yeasts, with exciting results both in health and in disease. A therapeutic potential for many gastrointestinal and extra-intestinal diseases has been recognized for selected yeast strains, such as Saccharomyces boulardii. This narrative review represents an overview of the new evidences regarding the “gut mycome”.

7 March 2018 in Digestive Diseases
Verified
Journal Article
Closed access
PDF file
Lucrezia LaterzaLucrezia Laterza
Lucrezia Laterza
APAnna Chiara Piscaglia
Anna Chiara Piscaglia
LMLaura Maria Minordi
Laura Maria Minordi
ISIolanda Scoleri
Iolanda Scoleri
LLLuigi Larosa
Luigi Larosa
FSFRANCO SCALDAFERRI
FRANCO SCALDAFERRI
Aim: To evaluate if a single and/or combined (clinical, endoscopic and radiological) assessment could predict clinical outcomes in Crohn’s disease (CD).